What do systematic reviews say?

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in disease‐free survival ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  HR 0.84 [0.65, 1.09]
  1 study · 828 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

The review found no eligible studies for this question.

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Non‐intensive vs intensive follow‐up

Summary of findings: Non‐intensive showed no clear difference in disease‐free survival compared with intensive follow‐up (low certainty).

• Follow‐up strategies for women treated for early breast cancer 2016 · Cochrane Headline outcomes only
  HR 0.84 [0.71, 1]
  2 studies · 2563 participants
  Low

Summary of findings: Decentralised vs centralised follow‐up

Summary of findings: Decentralised showed no clear difference in disease‐free survival compared with centralised follow‐up (moderate certainty).

• Follow‐up strategies for women treated for early breast cancer 2016 · Cochrane Headline outcomes only
  HR 1.06 [0.76, 1.47]
  2 studies · 1264 participants
  Moderate

OFS vs no OFS

OFS leads to lower disease‐free survival (DFS) Median compared with no OFS (high certainty).

• Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer 2020 · Cochrane Headline outcomes only
  HR 0.83 [0.77, 0.9]
  10 studies · 8899 participants
  High

Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy

Capecitabine‐containing regimens showed no clear difference in disease‐free survival (DFS)median compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).

• Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer 2021 · Cochrane Headline outcomes only
  HR 0.93 [0.86, 1.01]
  8 studies · 13547 participants
  Moderate

Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) vs no PMRT

• Post‐mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes 2023 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported